Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
3LN5v5y0bArJzwZm
